{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,15]],"date-time":"2026-09-15T03:06:10Z","timestamp":1789441570101,"version":"build-2803163510"},"reference-count":88,"publisher":"Ovid Technologies (Wolters Kluwer Health)","license":[{"start":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T00:00:00Z","timestamp":1754265600000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:p>Cardiac cachexia remains a phenomenon seen more particularly in New York Heart Association Classification class III or IV heart failure patients. This is frequently missed and written off as \u201cold age.\u201d It has a mortality rate of 50% within 18 months of diagnosis, so it is imperative to diagnose cardiac cachexia promptly. It remains elusive in the complexity of its underlying pathophysiology, from cytokine release from both the endocardium and the gut, with systemic implications. This review provides an analysis of cardiac cachexia: (1) definition and diagnostic criteria; (2) prevalence and mortality outcomes; (3) pathophysiology: biomarkers, neurohormonal activation, inflammatory cytokines, involvement of the gut, and iron deficiency anemia; (4) potential of reversibility; (5) differentiating cardiac cachexia from sarcopenia and frailty; (6) treatment: both pharmacologic and nonpharmacologic. This complex disease remains underrecognized.<\/jats:p>","DOI":"10.1097\/crd.0000000000001008","type":"journal-article","created":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T04:00:28Z","timestamp":1754280028000},"update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["Cardiac Cachexia: A Comprehensive Review"],"prefix":"10.1097","author":[{"given":"Julia S.","family":"Szinte","sequence":"first","affiliation":[{"name":"Department of Medicine, New York Presbyterian Brooklyn Methodist Hospital, Brooklyn, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Manish A.","family":"Parikh","sequence":"additional","affiliation":[{"name":"Department of Medicine, New York Presbyterian Brooklyn Methodist Hospital, Brooklyn, NY"},{"name":"Weill Department of Medicine, Weill Cornell Medicine, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William H.","family":"Frishman","sequence":"additional","affiliation":[{"name":"Department of Medicine, New York Medical College, Valhalla, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen J.","family":"Peterson","sequence":"additional","affiliation":[{"name":"Department of Medicine, New York Presbyterian Brooklyn Methodist Hospital, Brooklyn, NY"},{"name":"Weill Department of Medicine, Weill Cornell Medicine, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,8,4]]},"reference":[{"key":"R1-20250804","doi-asserted-by":"crossref","first-page":"363","DOI":"10.4070\/kcj.2024.0089","article-title":"Frailty, sarcopenia, cachexia, and malnutrition in heart failure.","volume":"54","author":"Maeda","year":"2024","journal-title":"Korean Circ J"},{"key":"R2-20250804","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1378\/chest.115.3.836","article-title":"Cardiac cachexia.","volume":"115","author":"Anker","year":"1999","journal-title":"Chest"},{"key":"R3-20250804","first-page":"heartjnl","article-title":"Association between cardiac cachexia and adverse outcomes in patients with heart failure: a meta-analysis of cohort studies.","volume":"111","author":"Liu","year":"2025","journal-title":"Heart"},{"key":"R4-20250804","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.amjms.2022.08.016","article-title":"The complex pathophysiology of cardiac cachexia: a review of current pathophysiology and implications for clinical practice.","volume":"365","author":"Thanapholsart","year":"2023","journal-title":"Am J Med Sci"},{"key":"R6-20250804","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1016\/j.clnu.2008.06.013","article-title":"Cachexia: a new definition.","volume":"27","author":"Evans","year":"2008","journal-title":"Clin Nutr (Edinburgh, Scotland)"},{"key":"R7-20250804","doi-asserted-by":"crossref","first-page":"2143","DOI":"10.1002\/jcsm.13291","article-title":"Prognostic impact of cachexia by multi\u2010assessment in older adults with heart failure: FRAGILE\u2010HF cohort study.","volume":"14","author":"Maekawa","year":"2023","journal-title":"J cachexia Sarcopenia Muscle"},{"key":"R8-20250804","doi-asserted-by":"crossref","first-page":"2536","DOI":"10.1002\/jcsm.13596","article-title":"Prognostic impact and prevalence of cachexia in patients with heart failure: a systematic review and meta-analysis.","volume":"15","author":"Prokopidis","year":"2024","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"R9-20250804","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1016\/S0140-6736(96)07015-8","article-title":"Wasting as independent risk factor for mortality in chronic heart failure.","volume":"349","author":"Anker","year":"1997","journal-title":"Lancet (London, England)"},{"key":"R10-20250804","doi-asserted-by":"crossref","first-page":"1118","DOI":"10.1177\/02692163221101748","article-title":"Exploring the prevalence, impact and experience of cardiac cachexia in patients with advanced heart failure and their caregivers: a sequential phased study.","volume":"36","author":"Carson","year":"2022","journal-title":"Palliat Med"},{"key":"R11-20250804","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.amjcard.2022.10.017","article-title":"Cachexia is associated with adverse outcomes in patients admitted with heart failure.","volume":"186","author":"Mohamad Alahmad","year":"2023","journal-title":"Am J Cardiol"},{"key":"R12-20250804","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.ijcard.2009.01.060","article-title":"The influence of age and sex on disease development in a novel animal model of cardiac cachexia.","volume":"133","author":"Palus","year":"2009","journal-title":"Int J Cardiol"},{"key":"R13-20250804","first-page":"73","article-title":"Sarcopenia in aging humans: the impact of menopause and disease.","volume":"50 Spec No","author":"Poehlman","year":"1995","journal-title":"J Gerontol A Biol Sci Med Sci"},{"key":"R14-20250804","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.3390\/cells11061039","article-title":"Interconnection between cardiac cachexia and heart failure-protective role of cardiac obesity.","volume":"11","author":"Soto","year":"2022","journal-title":"Cells"},{"key":"R15-20250804","doi-asserted-by":"crossref","first-page":"115664","DOI":"10.1016\/j.bcp.2023.115664","article-title":"Oxidative stress: roles in skeletal muscle atrophy.","volume":"214","author":"Zhang","year":"2023","journal-title":"Biochem Pharmacol"},{"key":"R16-20250804","doi-asserted-by":"crossref","first-page":"C1471","DOI":"10.1152\/ajpcell.1992.262.6.C1471","article-title":"Glucocorticoid-induced skeletal muscle atrophy in vitro is attenuated by mechanical stimulation.","volume":"262","author":"Chromiak","year":"1992","journal-title":"Am J Physiol"},{"key":"R17-20250804","doi-asserted-by":"crossref","first-page":"376","DOI":"10.1016\/j.cmet.2007.09.009","article-title":"The E3 ligase MuRF1 degrades myosin heavy chain protein in dexamethasone-treated skeletal muscle.","volume":"6","author":"Clarke","year":"2007","journal-title":"Cell Metab"},{"key":"R18-20250804","doi-asserted-by":"crossref","first-page":"e13761","DOI":"10.1002\/jcsm.13761","article-title":"Therapeutic targeting of decr1 ameliorates cardiomyopathy by suppressing mitochondrial fatty acid oxidation in diabetic mice.","volume":"16","author":"Lu","year":"2025","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"R19-20250804","doi-asserted-by":"crossref","first-page":"2249","DOI":"10.1093\/cvr\/cvae214","article-title":"GDF15 antagonism limits severe heart failure and prevents cardiac cachexia.","volume":"120","author":"Takaoka","year":"2024","journal-title":"Cardiovasc Res"},{"key":"R20-20250804","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1016\/S0167-5273(96)02873-2","article-title":"Elevated plasma levels of tumor necrosis factor in chronic heart failure with cachexia.","volume":"58","author":"Zhao","year":"1997","journal-title":"Int J Cardiol"},{"issue":"19 Suppl 3","key":"R21-20250804","first-page":"III352","article-title":"Elevated tumor necrosis factor-alpha and interleukin-6 in myocardium and serum of malfunctioning donor hearts.","volume":"102","author":"Birks","year":"2000","journal-title":"Circulation"},{"key":"R22-20250804","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1161\/01.CIR.100.11.1189","article-title":"Decreased expression of tumor necrosis factor-alpha in failing human myocardium after mechanical circulatory support: a potential mechanism for cardiac recovery.","volume":"100","author":"Torre-Amione","year":"1999","journal-title":"Circulation"},{"key":"R23-20250804","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1161\/01.RES.81.2.187","article-title":"Hemodynamic regulation of tumor necrosis factor-alpha gene and protein expression in adult feline myocardium.","volume":"81","author":"Kapadia","year":"1997","journal-title":"Circ Res"},{"key":"R24-20250804","doi-asserted-by":"crossref","first-page":"1900","DOI":"10.1002\/jcsm.13267","article-title":"Biomarkers and mechanisms associated with cancer-induced cardiac cachexia: a systematic review.","volume":"14","author":"Bagnall","year":"2023","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"R25-20250804","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1016\/j.immuni.2021.07.006","article-title":"Selective loss of resident macrophage-derived insulin-like growth factor-1 abolishes adaptive cardiac growth to stress.","volume":"54","author":"Zaman","year":"2021","journal-title":"Immunity"},{"key":"R26-20250804","doi-asserted-by":"crossref","first-page":"1489","DOI":"10.1210\/endo.142.4.8082","article-title":"Angiotensin II induces skeletal muscle wasting through enhanced protein degradation and down-regulates autocrine insulin-like growth factor I.","volume":"142","author":"Brink","year":"2001","journal-title":"Endocrinology"},{"key":"R27-20250804","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1097\/MAJ.0000000000000511","article-title":"Mechanisms of cachexia in chronic disease states.","volume":"350","author":"Yoshida","year":"2015","journal-title":"Am J Med Sci"},{"key":"R28-20250804","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1172\/JCI22324","article-title":"Muscle-specific expression of IGF-1 blocks angiotensin II-induced skeletal muscle wasting.","volume":"115","author":"Song","year":"2005","journal-title":"J Clin Invest"},{"key":"R29-20250804","first-page":"160","article-title":"Signaling in muscle atrophy and hypertrophy.","volume":"23","author":"Sandri","year":"2008","journal-title":"Physiology (Bethesda)"},{"key":"R30-20250804","first-page":"732","article-title":"Role of growth hormone in chronic heart failure: therapeutic implications.","volume":"1","author":"Volterrani","year":"2000","journal-title":"Ital Heart J"},{"key":"R31-20250804","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.hfc.2018.05.002","article-title":"Growth hormone therapy in heart failure.","volume":"14","author":"Salzano","year":"2018","journal-title":"Heart Fail Clin"},{"key":"R32-20250804","doi-asserted-by":"crossref","first-page":"3329","DOI":"10.1210\/jc.2009-0533","article-title":"Growth hormone deficiency in patients with chronic heart failure and beneficial effects of its correction.","volume":"94","author":"Cittadini","year":"2009","journal-title":"J Clin Endocrinol Metab"},{"key":"R33-20250804","doi-asserted-by":"crossref","first-page":"424","DOI":"10.1002\/ejhf.240","article-title":"Loss in body weight is an independent prognostic factor for mortality in chronic heart failure: insights from the GISSI\u2010HF and Val\u2010 HeFT trials.","volume":"17","author":"Rossignol","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"R34-20250804","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1002\/jcsm.12118","article-title":"Cardiac cachexia: hic et nunc.","volume":"7","author":"Loncar","year":"2016","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"R35-20250804","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/S0735-1097(01)01385-7","article-title":"Acquired growth hormone resistance in patients with chronic heart failure: implications for therapy with growth hormone.","volume":"38","author":"Anker","year":"2001","journal-title":"J Am Coll Cardiol"},{"key":"R36-20250804","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1054\/jcaf.2003.23","article-title":"Growth hormone resistance in chronic heart failure and its therapeutic implications.","volume":"9","author":"Cicoira","year":"2003","journal-title":"J Card Fail"},{"key":"R37-20250804","doi-asserted-by":"crossref","first-page":"127","DOI":"10.2169\/internalmedicine.45.1402","article-title":"Ghrelin, a novel growth hormone-releasing peptide, in the treatment of cardiopulmonary-associated cachexia.","volume":"45","author":"Nagaya","year":"2006","journal-title":"Intern Med"},{"key":"R38-20250804","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1161\/hc4201.097836","article-title":"Elevated circulating level of ghrelin in cachexia associated with chronic heart failure: relationships between ghrelin and anabolic\/catabolic factors.","volume":"104","author":"Nagaya","year":"2001","journal-title":"Circulation"},{"key":"R39-20250804","doi-asserted-by":"crossref","first-page":"H1643","DOI":"10.1152\/ajpheart.01042.2004","article-title":"GH-releasing peptides improve cardiac dysfunction and cachexia and suppress stress-related hormones and cardiomyocyte apoptosis in rats with heart failure.","volume":"289","author":"Xu","year":"2005","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"R40-20250804","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1097\/CRD.0000000000000534","article-title":"Back up at the pump? I have a gut feeling about this: a review of the gastrointestinal manifestations from congestive heart failure.","volume":"33","author":"Yee","year":"2025","journal-title":"Cardiol Rev"},{"key":"R41-20250804","doi-asserted-by":"crossref","first-page":"1561","DOI":"10.1016\/j.jacc.2007.07.016","article-title":"Altered intestinal function in patients with chronic heart failure.","volume":"50","author":"Sandek","year":"2007","journal-title":"J Am Coll Cardiol"},{"key":"R42-20250804","doi-asserted-by":"crossref","first-page":"2368","DOI":"10.1093\/eurheartj\/ehi389","article-title":"The importance of the gastrointestinal system in the pathogenesis of heart failure.","volume":"26","author":"Krack","year":"2005","journal-title":"Eur Heart J"},{"key":"R43-20250804","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.ijcard.2010.12.016","article-title":"Studies on bacterial endotoxin and intestinal absorption function in patients with chronic heart failure.","volume":"157","author":"Sandek","year":"2012","journal-title":"Int J Cardiol"},{"key":"R44-20250804","doi-asserted-by":"crossref","first-page":"177356","DOI":"10.1016\/j.ejphar.2025.177356","article-title":"Hepatokines and their role in cardiohepatic interactions in heart failure.","volume":"992","author":"Shouman","year":"2025","journal-title":"Eur J Pharmacol"},{"key":"R45-20250804","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1007\/s10741-022-10268-0","article-title":"Fibroblast growth factor 21 in heart failure.","volume":"28","author":"Tucker","year":"2023","journal-title":"Heart Fail Rev"},{"key":"R46-20250804","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.freeradbiomed.2023.07.007","article-title":"Selenoprotein P deficiency is associated with higher risk of incident heart failure.","volume":"207","author":"Jujic","year":"2023","journal-title":"Free Radic Biol Med"},{"key":"R47-20250804","doi-asserted-by":"crossref","first-page":"910","DOI":"10.1002\/ejhf.1154","article-title":"Iron deficiency impairs contractility of human cardiomyocytes through decreased mitochondrial function.","volume":"20","author":"Hoes","year":"2018","journal-title":"Eur J Heart Fail"},{"key":"R48-20250804","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1016\/j.celrep.2015.09.023","article-title":"Lethal cardiomyopathy in mice lacking transferrin receptor in the heart.","volume":"13","author":"Xu","year":"2015","journal-title":"Cell Rep"},{"key":"R49-20250804","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1016\/j.ijcard.2015.11.178","article-title":"The impact of iron deficiency and anaemia on exercise capacity and outcomes in patients with chronic heart failure. Results from the studies investigating co-morbidities aggravating heart failure.","volume":"205","author":"Ebner","year":"2016","journal-title":"Int J Cardiol"},{"key":"R50-20250804","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.1016\/j.ijcard.2013.04.181","article-title":"IRON-HF study: a randomized trial to assess the effects of iron in heart failure patients with anemia.","volume":"168","author":"Beck-da-Silva","year":"2013","journal-title":"Int J Cardiol"},{"key":"R51-20250804","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.3389\/fphys.2019.01294","article-title":"Hepcidin and anemia: a tight relationship.","volume":"10","author":"Pagani","year":"2019","journal-title":"Front Physiol"},{"key":"R52-20250804","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1161\/CIR.0000000000001193","article-title":"2023 ACC\/AHA\/ACCP\/HRS guideline for the diagnosis and management of atrial fibrillation: a report of the American College of Cardiology\/American Heart Association Joint Committee on clinical practice guidelines.","volume":"149","author":"Joglar","year":"2024","journal-title":"Circulation"},{"key":"R53-20250804","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1016\/j.ijcard.2016.08.318","article-title":"Association of cardiac cachexia and atrial fibrillation in heart failure patients.","volume":"223","author":"Ar\u00e1mbula-Garza","year":"2016","journal-title":"Int J Cardiol"},{"key":"R54-20250804","doi-asserted-by":"crossref","first-page":"e000078","DOI":"10.1161\/HAE.0000000000000078","article-title":"Managing atrial fibrillation in patients with heart failure and reduced ejection fraction: a scientific statement from the American Heart Association.","volume":"14","author":"Gopinathannair","year":"2021","journal-title":"Circ Arrhythm Electrophysiol"},{"key":"R55-20250804","doi-asserted-by":"crossref","first-page":"6418","DOI":"10.1096\/fj.202000196R","article-title":"Preserved capacity for satellite cell proliferation, regeneration, and hypertrophy in the skeletal muscle of healthy elderly men.","volume":"34","author":"Karlsen","year":"2020","journal-title":"FASEB J"},{"key":"R56-20250804","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.semcdb.2015.09.009","article-title":"Impaired regeneration: a role for the muscle microenvironment in cancer cachexia.","volume":"54","author":"Talbert","year":"2016","journal-title":"Semin Cell Dev Biol"},{"key":"R57-20250804","doi-asserted-by":"crossref","first-page":"1995","DOI":"10.1002\/jcsm.12803","article-title":"Prognostic score based on physical frailty in patients with heart failure: a multicenter prospective cohort study (FLAGSHIP).","volume":"12","author":"Yamada","year":"2021","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"R58-20250804","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1002\/jcsm.13306","article-title":"Frailty and heart failure: state-of-the-art review.","volume":"14","author":"Talha","year":"2023","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"R59-20250804","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.2337\/dci22-0014","article-title":"Heart failure: an underappreciated complication of diabetes. a consensus report of the American Diabetes Association.","volume":"45","author":"Pop-Busui","year":"2022","journal-title":"Diabetes Care"},{"key":"R60-20250804","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1002\/jcsm.13516","article-title":"Long-term insulin resistance is associated with frailty, frailty progression, and cardiovascular disease.","volume":"15","author":"Ke","year":"2024","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"R61-20250804","doi-asserted-by":"crossref","first-page":"1719","DOI":"10.1161\/ATVBAHA.123.319200","article-title":"Associations of homeostatic model assessment for insulin resistance trajectories with cardiovascular disease incidence and mortality.","volume":"43","author":"Lee","year":"2023","journal-title":"Arterioscler Thromb Vasc Biol"},{"key":"R62-20250804","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1016\/j.ijcard.2023.03.035","article-title":"Prevalence and prognostic impact of the coexistence of cachexia and sarcopenia in older patients with heart failure.","volume":"381","author":"Fujimoto","year":"2023","journal-title":"Int J Cardiol"},{"key":"R63-20250804","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1002\/jcsm.12191","article-title":"Effect of beta-adrenergic blockade with carvedilol on cachexia in severe chronic heart failure: results from the COPERNICUS trial.","volume":"8","author":"Clark","year":"2017","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"R64-20250804","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1161\/01.CIR.0000035653.72855.BF","article-title":"Effect of carvedilol on the morbidity of patients with severe chronic heart failure: results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study.","volume":"106","author":"Packer","year":"2002","journal-title":"Circulation"},{"key":"R65-20250804","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1016\/S1388-9842(00)00146-X","article-title":"The effects of enalapril\u2010digoxin\u2010diuretic combination therapy on nutritional and anthropometric indices in chronic congestive heart failure: preliminary findings in cardiac cachexia.","volume":"3","author":"Adigun","year":"2001","journal-title":"Eur J Heart Fail"},{"key":"R66-20250804","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.3390\/jcm13061670","article-title":"Sodium-glucose cotransporter-2 inhibitors in heart failure with malnutrition, frailty, sarcopenia, or cachexia.","volume":"13","author":"Horiuchi","year":"2024","journal-title":"J Clin Med"},{"key":"R67-20250804","doi-asserted-by":"crossref","first-page":"412","DOI":"10.1002\/jcsm.13393","article-title":"Efficacy of empagliflozin in heart failure with preserved ejection fraction according to frailty status in EMPEROR-Preserved.","volume":"15","author":"Coats","year":"2024","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"R68-20250804","doi-asserted-by":"crossref","first-page":"3224","DOI":"10.1161\/01.CIR.99.25.3224","article-title":"Safety and efficacy of a soluble P75 tumor necrosis factor receptor (Enbrel, etanercept) in patients with advanced heart failure.","volume":"99","author":"Deswal","year":"1999","journal-title":"Circulation"},{"key":"R69-20250804","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1016\/S0140-6736(97)09338-0","article-title":"Randomised investigation of effects of pentoxifylline on left-ventricular performance in idiopathic dilated cardiomyopathy.","volume":"351","author":"Sliwa","year":"1998","journal-title":"Lancet"},{"key":"R70-20250804","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/S0002-9149(99)00328-8","article-title":"Evaluation of growth hormone administration in patients with chronic heart failure secondary to coronary artery disease.","volume":"84","author":"Spallarossa","year":"1999","journal-title":"Am J Cardiol"},{"key":"R71-20250804","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1161\/01.CIR.99.1.18","article-title":"Recombinant growth hormone therapy in patients with ischemic cardiomyopathy: effects on hemodynamics, left ventricular function, and cardiopulmonary exercise capacity.","volume":"99","author":"Genth-Zotz","year":"1999","journal-title":"Circulation"},{"key":"R72-20250804","doi-asserted-by":"crossref","first-page":"783","DOI":"10.3390\/cells13090783","article-title":"Withaferin A as a potential therapeutic target for the treatment of angiotensin II-induced cardiac cachexia.","volume":"13","author":"Vemuri","year":"2024","journal-title":"Cells"},{"key":"R73-20250804","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1056\/NEJMoa0706201","article-title":"Rosuvastatin in older patients with systolic heart failure.","volume":"357","author":"Kjekshus","year":"2007","journal-title":"N Engl J Med"},{"key":"R74-20250804","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/S0140-6736(08)61240-4","article-title":"Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): a randomised, double-blind, placebo-controlled trial.","volume":"372","author":"Tavazzi","year":"2008","journal-title":"Lancet"},{"key":"R75-20250804","doi-asserted-by":"crossref","first-page":"e263","DOI":"10.1016\/j.jacc.2021.12.012","article-title":"2022 AHA\/ACC\/HFSA Guideline for the management of heart failure.","volume":"79","author":"Heidenreich","year":"2022","journal-title":"J Am Coll Cardiol"},{"key":"R76-20250804","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.jjcc.2022.11.001","article-title":"Nutritional management of heart failure.","volume":"81","author":"Kida","year":"2023","journal-title":"J Cardiol"},{"key":"R77-20250804","doi-asserted-by":"crossref","first-page":"542","DOI":"10.1016\/j.jamda.2013.05.021","article-title":"Evidence-based recommendations for optimal dietary protein intake in older people: a position paper from the PROT-AGE study group.","volume":"14","author":"Bauer","year":"2013","journal-title":"J Am Med Dir Assoc"},{"key":"R78-20250804","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1007\/s13539-010-0008-0","article-title":"The effects of a high-caloric protein-rich oral nutritional supplement in patients with chronic heart failure and cachexia on quality of life, body composition, and inflammation markers: a randomized, double-blind pilot study.","volume":"1","author":"Rozentryt","year":"2010","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"R79-20250804","first-page":"CD015749","article-title":"Multimodal interventions for cachexia management.","volume":"3","author":"Reid","year":"2025","journal-title":"Cochrane Database Syst Rev"},{"key":"R80-20250804","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1002\/jcsm.13221","article-title":"Sarcopenia and cardiovascular diseases: a systematic review and meta-analysis.","volume":"14","author":"Zuo","year":"2023","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"R81-20250804","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1016\/j.healun.2022.12.004","article-title":"The 2023 International Society for Heart and Lung Transplantation Guidelines for mechanical circulatory support: a 10-year update.","volume":"42","author":"Saeed","year":"2023","journal-title":"J Heart Lung Transplant"},{"key":"R82-20250804","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1016\/j.jchf.2024.03.003","article-title":"Controversies and conundrums in cardiac cachexia.","volume":"12","author":"Ilonze","year":"2024","journal-title":"JACC Heart Fail"},{"key":"R83-20250804","doi-asserted-by":"crossref","first-page":"e009012","DOI":"10.1161\/CIRCHEARTFAILURE.121.009012","article-title":"Skeletal muscle mass recovery early after left ventricular assist device implantation in patients with advanced systolic heart failure.","volume":"15","author":"Vest","year":"2022","journal-title":"Circ Heart Fail"},{"key":"R84-20250804","doi-asserted-by":"crossref","first-page":"297","DOI":"10.1007\/s13539-014-0155-9","article-title":"Ventricular assist device implantation improves skeletal muscle function, oxidative capacity, and growth hormone\/insulin-like growth factor-1 axis signaling in patients with advanced heart failure.","volume":"5","author":"Khawaja","year":"2014","journal-title":"J Cachexia Sarcopenia Muscle"},{"key":"R85-20250804","doi-asserted-by":"crossref","first-page":"S57","DOI":"10.1016\/j.cardfail.2016.06.173","article-title":"Cachexia is common in ventricular assist device recipients but not predictive of mortality.","volume":"22","author":"Sundararajan","year":"2016","journal-title":"J Card Fail"},{"key":"R86-20250804","doi-asserted-by":"crossref","first-page":"e029086","DOI":"10.1161\/JAHA.122.029086","article-title":"Cardiac cachexia in left ventricular assist device recipients and the implications of weight gain early after implantation.","volume":"12","author":"Vest","year":"2023","journal-title":"J Am Heart Assoc"},{"key":"R87-20250804","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1093\/eurjhf\/hfp088","article-title":"Ghrelin resistance occurs in severe heart failure and resolves after heart transplantation.","volume":"11","author":"Lund","year":"2009","journal-title":"Eur J Heart Fail"},{"key":"R88-20250804","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1093\/eurjhf\/hfp044","article-title":"Growth hormone resistance in severe heart failure resolves after cardiac transplantation.","volume":"11","author":"Lund","year":"2009","journal-title":"Eur J Heart Fail"},{"key":"R89-20250804","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1016\/j.healun.2005.02.003","article-title":"Reversibility of cardiac cachexia after heart transplantation.","volume":"24","author":"Habedank","year":"2005","journal-title":"J Heart Lung Transplant"}],"container-title":["Cardiology in Review"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000001008","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,4]],"date-time":"2025-08-04T04:00:39Z","timestamp":1754280039000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CRD.0000000000001008"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,4]]},"references-count":88,"URL":"https:\/\/doi.org\/10.1097\/crd.0000000000001008","relation":{},"ISSN":["1538-4683"],"issn-type":[{"value":"1538-4683","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,8,4]]}}}